Company Overview and News

 
Monadelphous wins $240m BHP contract

2018-10-03 businessnews.com.au
Engineering companies Monadelphous Group and Downer EDI have announced separate maintenance contracts with iron ore miner BHP Billiton.
DOW MOPHY DNERY BLT BHP BHPBF MDPHF DOW BBL BHP BHPLF MND

 
Adelaide North Terrace tram extension cost blows out

2018-09-27 abc.net.au
The cost of Adelaide's long-delayed North Terrace tram extension could blowout by more than $44 million, according to South Australian Infrastructure Minister Stephan Knoll.
DOW DNERY DOW

 
Downer wins $286m Millmerran mine management contract

2018-09-05 australianmining.com.au
Downer EDI has been awarded a contract extension for its mining services at the Commodore open cut coal mine in South East Queensland.
DOW OZMLF DNERY DOW OZL

 
Downer EDI, Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-16 seekingalpha
The following slide deck was published by Downer EDI, Ltd. ADR in conjunction with their 2018 Q4 earnings call.
DOW DNERY DOW

 
Royal Adelaide Hospital services in doubt after contractor's $93.8m loss

2018-08-16 abc.net.au
The future of catering and cleaning services at the Royal Adelaide Hospital are in question, after revelations the company contracted to run them has lost $93.8 million on the contract.
DOW DNERY DOW

 
Downer wins $120m Cobar Management contract

2018-08-09 australianmining.com.au
Downer EDI has secured a $120 million contract to provide mining services at Cobar Management’s CSA underground copper mine in New South Wales.
DOW DNERY DOW

 
Gold Road Resources completes final cost estimate for the Gruyere Gold Project

2018-07-30 proactiveinvestors.com.au
Gold Road Resources Ltd (ASX:GOR) has received the independent third party review of the definitive estimate for its Gruyere Gold Project, representing an estimate of costs to the end of project commissioning.
DOW ELKMF GFI.WI DNERY GOR DOW GFI GFIOF APA

 
OZ Minerals keeps Carrapateena on track

2018-07-18 australianmining.com.au
OZ Minerals’ development of the Carrapateena copper-gold project in South Australia is taking shape as planned.
DOW OZMLF DNERY AVB DOW OZL

 
Adani CEO’s son claims Carmichael mine funded

2018-07-18 australianmining.com.au
India’s Adani has reportedly completed financing for the Carmichael coal mine and is close to securing funds for the rail component of the project.
DOW DNERY DOW

 
Downer wins long-term maintenance contract

2018-07-16 australianmining.com.au
Chevron has awarded Downer EDI a five-year contract to provide maintenance and support services at its Western Australian operations.
DOW DNERY DOW

5
Receivers probe 13 ex-Hawkins companies, call for creditors issued

2018-05-30 nzherald.co.nz
The receivers of 13 businesses previously part of New Zealand's second-largest construction company Hawkins are calling for creditors and say the directors of the businesses are giving their full support in the process.
DOW DNERY DOW

5
Ex-Hawkins Orange-H placed in receivership by shareholder; owes creditors $30 million

2018-05-11 nzherald.co.nz
Orange-H Group, the McConnell entity set up to run down the residual Hawkins assets after the sale to Downer Group, has been tipped into receivership by its shareholder and creditor just 10 days after being ordered to pay $13.4 million over a leaky school.
DOW DNERY DOW

5
OZ closes Prominent Hill open pit

2018-04-17 australianmining.com.au
OZ Minerals has completed its planned closure of the Prominent Hill open pit in South Australia.
DOW OZMLF DNERY AVB DOW OZL

5
OZ Minerals awards $660m Carrapateena contract to Downer

2018-04-16 australianmining.com.au
Downer EDI will deliver underground mining services at OZ Minerals’ Carrapateena copper-gold project in South Australia after being awarded a $660 million contract at the operation.
DOW OZMLF DNERY DOW OZL

5
New Century awards ‘landmark’ training contract at Century mine

2018-03-28 australianmining.com.au
New Century Resources has awarded what has been described as a landmark contract to the Waanyi ReGen Joint Venture (WRJV) to provide training services for Aboriginal and Torres Strait Islander people local to the Century zinc mine in Queensland.
DOW DNERY DOW NCRE

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 260737101